Liquidia (NASDAQ:LQDA) Sees Large Volume Increase After Analyst Upgrade

Liquidia Corporation (NASDAQ:LQDA) saw unusually-strong trading volume on Wednesday after BTIG Research upgraded the stock from a neutral rating to a buy rating. BTIG Research now has a $70.00 price target on the stock. Approximately 7,091,868 shares traded hands during trading, an increase of 235% from the previous session’s volume of 2,115,398 shares. The stock last traded at $34.1210 and had previously closed at $26.81.

Several other brokerages have also issued reports on LQDA. Raymond James Financial restated an “outperform” rating on shares of Liquidia in a report on Thursday, October 8th. Royal Bank Of Canada set a $130.00 target price on shares of Liquidia in a research report on Friday, July 24th. Jefferies Financial Group raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday, October 1st. Weiss Ratings upgraded shares of Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $30.00 price target (down from $108.00) on shares of Liquidia in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $79.69.

Insider Transactions at Liquidia

In related news, insider Rajeev Saggar sold 9,218 shares of the firm’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $262,528.64. Following the completion of the transaction, the insider directly owned 126,368 shares in the company, valued at $3,598,960.64. This trade represents a 6.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Krepp sold 5,245 shares of Liquidia stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $149,377.60. Following the completion of the transaction, the insider directly owned 115,241 shares of the company’s stock, valued at approximately $3,282,063.68. This represents a 4.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 745,194 shares of company stock worth $41,081,702. 25.60% of the stock is owned by corporate insiders.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six pending patent, antitrust, trade-secret and contract disputes with United Therapeutics. The agreement allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH), reducing the risk of a market disruption or prolonged litigation. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA net sales reached $222.7 million, and Liquidia had $396.1 million in cash and cash equivalents at September 30. Management said it expects to fund settlement payments and clinical development from cash and operating sales without issuing new financing. Liquidia United Therapeutics litigation settlement
• Positive Sentiment: BTIG upgraded Liquidia from “neutral” to “buy” with a $70 price target, while Needham maintained a “buy” rating and lowered its target to $58. Both targets imply substantial upside based on the company’s recent trading level.
• Neutral Sentiment: Liquidia plans to continue developing YUTREPIA and its investigational L606 formulation, potentially supporting longer-term growth beyond the current PAH business.
• Negative Sentiment: The settlement requires Liquidia to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust claims. The payments will substantially reduce the company’s cash balance and could limit investment flexibility.
• Negative Sentiment: Liquidia agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing some commercial opportunities.
• Neutral Sentiment: The CEO, CFO and other insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax obligations from vested equity awards. Because the sales were not discretionary open-market transactions, they are a limited standalone signal, although recent insider activity remains heavily weighted toward selling.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Globeflex Capital L P acquired a new position in shares of Liquidia during the second quarter worth about $175,000. Nykredit A S purchased a new stake in shares of Liquidia during the second quarter worth approximately $177,000. Fluent Financial LLC purchased a new stake in shares of Liquidia during the second quarter worth approximately $287,000. WINTON GROUP Ltd purchased a new stake in shares of Liquidia during the second quarter worth approximately $335,000. Finally, Fulcrum Equity Management acquired a new stake in Liquidia in the second quarter valued at approximately $399,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Trading Up 29.8%

The company’s fifty day moving average is $63.40 and its two-hundred day moving average is $61.76. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of 25.41 and a beta of 0.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same period in the prior year, the company posted ($0.49) earnings per share. The company’s revenue for the quarter was up 1842.1% on a year-over-year basis. On average, research analysts predict that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).